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Abstract
Background Wernicke’s encephalopathy (WE) is an
acute neuropsychiatric condition caused by depleted
intracellular thiamine, most commonly arising in chronic
alcohol misusers, who may present to emergency depart-
ments (EDs) for a variety of reasons. Guidelines recom-
mend a minimum 5-day course of intravenous (IV)
thiamine in at-risk patients unless WE can be excluded.
Objective To estimate the cost impact on the UK public
sector (NHS and social services) of a 5-day course of IV
thiamine, vs a 2- and 10-day course, in harmful or
dependent drinkers presenting to EDs.
Methods A Markov chain model compared expected
prognosis of patients under alternative admission strategies
over 35 years. Model inputs were derived from a
prospective cohort study, expert opinion via structured
elicitation and NHS costing databases. Costs (2012/2013
price year) were discounted at 3.5 %.
Results Increasing treatment from 2 to 5 days increased
acute care costs but reduced the probability of disease
progression and thus reduced the expected net costs by
GBP87,000 per patient (95 % confidence interval
GBP19,300 to GBP172,300) over 35 years.
Conclusions Increasing length of stay to optimize IV
thiamine replacement will place additional strain on acute
care but has potential UK public sector cost savings. Social
services and the NHS should explore collaborations to
realise both the health benefits to patients and savings to
the public purse.
Key Points for Decision Makers
Guidelines state that suspected Wernicke’s
encephalopathy should be treated with 5 days of IV
thiamine.
Different admission strategies in at-risk patients
were modelled.
Admissions of 5 instead of 2 days may reduce cost
per patient by GBP87,000 over 35 years.
Every extra GBP1 spent in acute care is estimated to
save GBP6 in future social care costs.
1 Introduction
Wernicke’s encephalopathy (WE) is an acute neuropsy-
chiatric condition caused by an initially reversible brain
lesion due to ‘overwhelming metabolic demands on cells
with depleted intracellular thiamine’ [1]. Autopsy studies
estimate the prevalence of WE in the general population at
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between 0.4 % and approximately 2 %, with lower rates in
Western Europe and the higher rates observed in Australia
[2–4]. Among chronic alcoholics the prevalence rises to
14 % [5]. The diagnosis of affected patients before death
has been reported to be as low as 5 % [6], the acute mor-
tality rate is around 20 % [6, 7], while approximately 75 %
of patients are left with permanent brain damage and dis-
ability [6, 7]. WE is most commonly seen in chronic
alcohol misusers [8] who are deficient in dietary thiamine
[9, 10]. The condition can be easily missed if not sus-
pected, owing to the similarity of the symptoms to other
alcohol-related effects (e.g. intoxication, abnormal gait and
other neurological disorders or head trauma). Although
factors predisposing to thiamine deficiency have been
identified [11], ignoring these symptoms and signs can lead
to loss of consciousness, coma and death [12].
No sensitive and robust screening tool that can be
administered in acute care settings, such as emergency
department (ED) consultations, is currently available. The
classic signs of WE were originally described as a triad,
comprising abnormal mental state, gait ataxia (uncoordi-
nated movement) and ophthalmoplegia (paralysis/weak-
ness of the muscles of the eye). Notably, however, all three
symptoms are only seen in approximately 10–16.5 % of
cases [1, 6, 13], thus reliance on the presence of the triad
leads to under-diagnosis.
Depending on the severity of the illness at presentation,
patients are typically seen first in the ED although diagnosis of
WE can take place in a community setting via GP consulta-
tions, typically with subsequent referrals to acute or specialist
care. Patients with WE present in a variety of ways, including
with head injuries (e.g. skull fractures), vomiting, an inability
to walk (resulting in falls), confusion, fits, infections or
complications of chronic liver disease and dietary deficiencies
[11, 12, 14]. In addition, they may present with a variety of
psychiatric illnesses, necessitating a psychiatric assessment.
Depending on clinical assessment [that may include labora-
tory investigations and computerised tomography (CT)] and
after initial resuscitation in the ED, patients may be admitted
under the appropriate specialist teams. For those departments
with an alcohol nurse specialist, an assessment provides
additional perspectives on diagnosis and appropriate treat-
ment. A joint assessment with the liaison psychiatric team
would be ideal for an holistic approach [15].
If untreated or inadequately treated, approximately
85 % of patients with WE are at risk of developing the
chronic form of the condition, Korsakoff’s syndrome (KS),
also known as Korsakoff’s psychosis (KP), a mostly irre-
versible neuropsychiatric condition that often results in the
patient being admitted to long-term care [6, 7, 16]. The
acute and chronic stages together are referred to as Wer-
nicke–Korsakoff syndrome (WKS).
Treatment is with parenteral vitamin supplements,
specifically intravenous (IV) thiamine (vitamin B1) [7].
Pabrinex Intravenous High Potency Injection (Archi-
medes Pharma UK Ltd) is the only IV preparation of thi-
amine marketed in the UK and it is presented as two
ampoules. Two or three pairs of ampoules are mixed with
50–100 mL saline and administered to the patient in one
dose, preferably via a drip infusion over 30 min, repeated
every 8 h [17]. However, the duration of treatment is not
specified in the Summary of Product Characteristics
(SmPC) [17], and guidelines and hospital protocols on the
optimal duration vary. The British National Formulary
(BNF) recommends maintaining this dose for the first
2 days, reducing to one pair of ampoules daily for at least
another 5 days or ‘for as long as improvement continues’
[18]. The National Institute for Health and Care Excellence
(NICE) recommends a minimum 5-day course of par-
enteral administration unless WE can be excluded [19].
This guidance reflects the challenges of clinical assessment
of WE, the limited evidence base and the limited window
of opportunity for replenishment of thiamine in at-risk
patients during contact with acute care settings.
Pressure on beds in the acute setting is also likely to
affect the decision to admit a patient, especially where a
definitive diagnosis of WE cannot be made. Whilst other
aetiologies exist, the most common presentation is asso-
ciated with chronic alcohol misuse [1, 6]. Patients may be
of no fixed abode and, once discharged, such patients are
often lost to follow-up, unless they re-present at an ED in
the future. It is reasonable to suppose that a patient who
receives less than the recommended 5-day course (as per
NICE guidelines) [19] may remain at risk of developing the
chronic form of the disease (KS) and, so, is at risk of
admission to long-term institutional care.
The purpose of this study was to estimate the long-term
cost impact to the public sector in the UK (defined as NHS
and social services costs over 35 years) of hospital
admissions during which time patients can complete a
minimum 5-day course of thiamine treatment, compared
with current practice, defined here as 2 days of treatment.
2 Methods
A cost model was developed to compare the expected long-
term (35 years) costs to the public sector (defined as NHS
and social services) of different IV thiamine replacement
admission strategies: 2 vs 5 vs 10 days. The modelled
patient population was defined as harmful or dependent
drinkers presenting to the ED for any reason, who are
malnourished or at risk of malnourishment or who have
decompensated liver disease [19]. The base-case scenario
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was of a 30-year-old male, chosen to represent a ‘typical’
patient (authors’ assumption).
2.1 Systematic Review
A review of the published literature, using systematic
methodology, was conducted on the basis of an adapted
version of the Cochrane Drugs and Alcohol Group’s search
strategy [20]. Relevant terms for the population [e.g. ‘Wer-
nicke Encephalopathy’ (MeSH), ‘Drinking Behaviour’
(MeSH)] were crossed with outcome concepts, study type
concepts and intervention concepts, as appropriate. The
search included MEDLINE (January 1966 to March 2014)
and Embase (January 1974 to March 2014) databases, as
well as the Cochrane Library, and identified 35 potentially
useful documents. Hand searching and supporting targeted
searches identified an additional five studies. Of these, full-
text versions of 31 articles were requested. The literature
review protocol, which includes the full search terms,
PRISMA diagram and summary of findings are provided in
Electronic Supplementary Material 1 and 2.
Of note was the complete absence of well-conducted
randomised controlled trials (RCTs) demonstrating the
efficacy of IV thiamine in the prevention and/or treatment
of WKS. The only study included in a Cochrane systematic
review [21] evaluated the impact of intramuscular thiamine
on working memory, 2 days after treatment [22].
The initial draft of the model was reviewed for plausi-
bility, before being populated with existing data and evi-
dence gaps identified. Evidence gaps were bridged using a
formal structured elicitation process, the Sheffield Elicita-
tion Framework [23], the results of which are summarized
in Electronic Supplementary Material 3 and reported in full
elsewhere (manuscript in preparation).
2.2 Comparator Interventions
Admission to hospital for 5 days or delayed dis-
charge/transfer to a specific alcohol unit to allow com-
pletion of a 5-day treatment course was included as a
scenario to ensure compliance with the NICE-recom-
mended IV thiamine replacement strategy [19]. The cur-
rent standard of care varies between centres and patients;
globally, compliance with treatment recommendations
appears to be low overall [24–29]. For the purpose of this
analysis, therefore, two alternative comparator scenarios
were evaluated: a 2-day and a 10-day admission strategy
with associated IV thiamine replacement. For example,
the 2-day admission scenario may represent a situation in
which a patient with suspected WE arrives at the ED with
a minor traumatic injury, receives IV thiamine, and is
admitted for observation overnight before being dis-
charged the following day.
As per the licensed dose of Pabrinex, treatment of
admitted patients was assumed to consist of three pairs of
IV thiamine ampoules, administered three times daily for
the entire length of admission [17], as well as oral mag-
nesium and multivitamins as detailed below.
2.3 Model Structure
A five-state Markov chain model was developed (Fig. 1).
This models the prognosis of a simulated patient or cohort
of patients by dividing the course of their disease into five
discrete states. Patients present to the ED (state 1), with an
admission of 2, 5 or 10 days (depending on the scenario
being modelled). From state 1, a patient can either be
discharged to the community (state 2), develop KS
requiring a community-based care package (state 3),
Fig. 1 Schematic of Markov
model. KS Korsakoff’s
syndrome, LT long-term. Letters
a to e refer to sets of parameters
as described in the text and
Table 1
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develop KS requiring long-term institutional care (state 4)
or die (state 5). The possible transitions from one state to
another are represented by the arrows in Fig. 1. Access to
long-term institutional care and community-based care was
assumed only through an admission from the acute setting
(state 1).
The transition period was defined as 3 months, and the
probabilities of a transition in each period were based on
evidence from the literature and expert opinion, as
described below. The 3-month transition period was con-
sidered appropriate given the nature of the disease and
likely time period for transition between states. A cost was
assigned to each state. Totalling the cost of each state
multiplied by the time spent in each state, while dis-
counting future costs to present values, provided an esti-
mate of the expected life-time cost of a patient using the
base-case (no treatment) scenario. The model was repeated
under alternative treatment scenarios of 2, 5 and 10 days
with substitution of relevant costs and transition probabil-
ities to allow comparison of the expected long-term costs.
2.4 Transition Probabilities
The transitions illustrated in Fig. 1 are grouped (from a–e)
and were estimated from a review of the literature, expert
opinion (via a formal elicitation panel) and standard NHS
databases; a total of nine sources were utilised [16, 30–37].
The key published source for evidence on the natural his-
tory of the disease was a 10-year prospective cohort study
by Victor and colleagues [16]. The proportion of the target
population with WE and the effect of IV thiamine treat-
ment were based on expert elicitation (Electronic Supple-
mentary File 3). The re-presentation rate of patients was
based on a study conducted in north-west England [35],
and costs were extracted from standard NHS and social
services unit costs publications [36, 37].
The derivation of each set of transition probabilities
labelled a–e in Fig. 1 is fully described in Electronic
Supplementary Materials 4 and 5. Briefly, parameter ‘a’
relates to acute mortality (within 3 months of presentation),
is assumed temporally stationary and is based on data from
Victor et al. [16]. Parameter set ‘b’ relates to longer-term
mortality and varies with time (age of simulated patient),
drawing on life table data [30], adjusted for the relative risk
of all-cause mortality in patients with alcoholism [31, 32].
Parameter set ‘c’ relates to destination on discharge from
acute care, is temporally stationary and is based on data
from Victor et al. [16]. Parameter set ‘d’ relates to partial
or complete recovery from KS and is based on data from
Victor et al., with a declining probability of recovery with
time since admission (modelled using tunnel states).
Finally, parameter set ‘e’ relates to patient re-presentation
at the ED from the community (so-called ‘revolving door’
patients) and is indirectly informed by a prospective cohort
study in England [35].
Expert panel opinion on the probability of response was
used to construct a dose–response curve with associated
uncertainty. The relative risk of development of KS by
days of treatment was estimated by dividing the proba-
bility of response from one treatment dose by the proba-
bility of response from another (see Table 1). Details of
the elicitation process and associated calculations are
provided in Electronic Supplementary File 3. The relative
risk of response for 2, 5 and 10 days of treatment was
used to adjust parameter set ‘c’ in the three comparator
scenarios.
2.5 Cost
Cost inputs to the model included the cost of the index ED
attendance, admission, long-term institutional care and
community care packages. The price year of the analysis
was 2012/13, with costs incurred after the first year of the
analysis discounted at a rate of 3.5 % per annum (the rate
recommended by HM Treasury [38] and NICE [39]).
2.5.1 Index Attendance and Admission
In 2012/13, the mean cost of an ED attendance was
GBP115 [37]. On the first day, following admission,
patients were assumed to receive three pairs of IV thiamine
ampoules three times daily (GBP1.96 per vial [40]),
administered via an IV drip infusion over 30 min each time
[requiring an IV catheter (GBP1.80), giving set (GBP1.95)
and saline (GBP0.97)], oral multivitamins (GBP0.05 per
day), IV magnesium (GBP1.10 per day), fluid and elec-
trolyte replacement, and monitoring of electrolytes, blood
pressure and renal function. Treatment cost on subsequent
days was assumed to be identical, except that the catheter
was assumed to remain in situ.
The cost was estimated as the total of the ED attendance
plus a cost per bed-day and drugs (IV thiamine, multivi-
tamins and magnesium supplements) as described in
Table 1. The unit cost of a bed-day was based on the mean
cost of excess bed-days (where patients exceed the national
tariff trim point) for elective general surgery inpatients for
the relevant diagnostic codes. It was, therefore, assumed to
include overhead costs and routine nursing activities and
monitoring, so no additional cost was assigned for
preparing, inserting and monitoring IV drips (although
consumables were costed separately).
2.5.2 Long-Term Institutional and Community Care
The cost of long-term institutional care for a patient with
KS was estimated at GBP816 per week, or GBP10,608 per
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Table 1 Model inputs
Model input Distribution Mean/
base case
SE Parameter
1a
Parameter
2a
Source/notes
RR all-cause mortality, chronic alcohol
misuser, male
LogNormal 1.56 0.270 0.445 0.270 Rehm et al. [31] used to calculate
LT mortality (transition set b)
RR all-cause mortality, chronic alcohol
misuser, female
LogNormal 2.26 0.342 0.815 0.342 Rehm et al. [31] used to calculate
LT mortality (transition set b)
Prevalence alcohol misuse, male Constant 6 % – – – Drummond et al. [32] Input to
calculate LT mortality (transition
set b)
Prevalence alcohol misuse, female Constant 2 % – – – Drummond et al. [32] Input to
calculate LT mortality (transition
set b)
Acute mortality among patients with
WKS
Beta 10.6 % 1.9 % 26 245 Input to transition ab
Prevalence of WKS in chronic alcohol
misusers attending the ED
Scaled beta 19.0 % 21.72 % 2.359 1.865 Range: 5, 30
Source: expert elicitation
Input to transition set ab
Proportion of patients presenting at an
ED developing KS, no thiamine
Beta 84.4 % 2.65 % 157 29 Victor et al. [16]
Input to transition set cb
Proportion of patients with KS admitted
to long-term care
Beta 26.0 % 4.28 % 27 77 Victor et al. [16]
Input to transition set cb
Probability of recovery from KS and
discharge to community care or
community
(see Electronic Supplementary Material 5) Parameter set d
Probability of re-attendance at an ED
once discharged
Uniform 31.6 % – 10 % 50 % Assumption based on Pirmohamed
et al. 2000 [35]
Transition set eb
Relative risk of development of KS,
10 days of treatment vs 0
Normal 0.050 0.013 0.050 0.013 Elicitation panelc
9 days vs 0 Normal 0.054 0.016 0.054 0.016 Elicitation panelc
8 days vs 0 Normal 0.058 0.019 0.058 0.019 Elicitation panelc
7 days vs 0 Normal 0.061 0.022 0.061 0.022 Elicitation panelc
6 days vs 0 Normal 0.065 0.025 0.065 0.025 Elicitation panelc
5 days vs 0 Normal 0.069 0.028 0.069 0.028 Elicitation panelc
4 days vs 0 Normal 0.281 0.073 0.281 0.073 Elicitation panelc
3 days vs 0 Normal 0.493 0.119 0.493 0.119 Elicitation panelc
2 days vs 0 Normal 0.705 0.165 0.705 0.165 Elicitation panelc
1 day vs 0 Normal 0.852 0.148 0.852 0.148 Elicitation panelc
Cost of ED attendance (GBP) Gamma 115 28.20 16.4681 6.9489 NHS Reference Costs 2013 [37]
Cost of long-term institutional care, per
3 months (GBP)
Uniform 10,608 – 8000 12,000 PSSRU [36]
Cost of community care per 3 months
(GBP)
Uniform 5941 – 2500 6500 PSSRU [36]
Cost of inpatient bed-day (GBP) Gamma 279 43.03 42.0417 6.6363 NHS Reference Costs 2013 [37]d
Thiamine preparation, per pair of
ampoules
Constant GBP1.96 – BNF 67 [40]e
Multivitamins, per day Constant GBP0.054 – BNF 67 [40]f
Magnesium supplement, per day Constant GBP1.10 – BNF 67 [40]g
IV giving set Constant GBP1.95 – Representative costh
Saline 1 L Constant GBP0.97 – BNF 67 [40]i
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3-month period (13 weeks). This value was based on the
cost of caring for a person with mental health problems in a
local authority care home [36]. The cost of community care
was estimated at GBP457 per week or GBP5941 per
3-month period. This value was based on the mean cost of
a social care support package for people with mental health
problems [36].
2.6 Analytic Approach
2.6.1 Base Case
The analysis compared three scenarios: 2-, 5- and 10-day
admissions for administration of IV thiamine in a 30-year-
old male. Analysis was based around Monte Carlo simu-
lation of model inputs: probability distributions were
assigned to model input parameters as shown in Table 1.
These distributions were sampled repeatedly (1000 times)
and the cost for each scenario was recorded. The mean and
the 2.5th and 97.5th centiles of the cost under each scenario
were interpreted as the expected cost and 95 % confidence
interval (CI). One thousand iterations were confirmed as
sufficient to achieve stability of results by repeatedly run-
ning sets of simulations and comparing the results.
2.6.2 Sensitivity Analysis
One-way sensitivity analysis was also undertaken, com-
paring 2- vs 5-day admissions, varying model inputs indi-
vidually between plausible ranges. The values, at which a
5-day admission would become more costly than a 2-day
admission, where these exist, were identified in a threshold
analysis.
2.6.3 Budget Impact Analysis
The predicted budget impact for health and social services
relating to a representative ED unit with 500 patients pre-
senting per annum, increasing by 10 patients each year,
was estimated. This is intended to represent a ‘typical’ ED
with one or two patients presenting each day (authors’
assumption).
3 Results
3.1 Base Case
The expected cost of care over 35 years following the
admission for 2 days of a harmful or dependent drinker
presenting to the ED, who is malnourished or at risk of
malnourishment or has decompensated liver disease and in
whom WE cannot be excluded, is approximately
GBP123,700 (present value, discounted at 3.5 %; 95 % CI
GBP50,000–GBP221,300, Table 2). Of this cost, approxi-
mately GBP730 is the cost of the index ED attendance and
admission. The cost of repeat attendances to the ED over
the following 35 years totals approximately GBP8700. The
expected cost of long-term care is approximately
GBP114,300, of which GBP96,700 is accounted for by
long-stay institutional care, the remainder being commu-
nity-based care.
If the patient is admitted for an extra 3 days (5-day
admission) to receive a longer course of IV thiamine
plus associated care, the cost of the index attendance and
admission rises to approximately GBP1700. The expec-
ted cost of future attendances to the ED and admissions
Table 1 continued
Model input Distribution Mean/
base case
SE Parameter
1a
Parameter
2a
Source/notes
IV catheter Constant GBP1.80 – Representative costj
BNF British National Formulary, ED emergency department, IV intravenous, KS Korsakoff’s syndrome, LT long-term, PSSRU Personal Social
Services Research Unit, RR relative risk, SE standard error, WKS Wernicke–Korsakoff syndrome
a Parameters for each distribution are as follows: normal- mean, standard error; beta- successes, failures; scaled beta- as for beta, with range for
distribution reported in source/notes column; gamma- shape, scale; lognormal- natural log of mean, standard error of natural log of mean;
uniform- lower and upper bounds
b Transition as per Fig. 1
c See Electronic Supplementary File 3 for further details of the elicitation panel
d Based on mean of elective inpatient general surgery excess bed-day costs
e Pabrinex IV, GBP1.96 per pair of ampoules
f Multivitamin capsules, GBP1.50 per 28-capsule pack
g Non-proprietary magnesium maximum dose 160 mmol IV over 5 days
h http://www.dsmedical.co.uk/iv_giving_set
i Non-proprietary 1 L saline
j Venflon, www.vivomed.com
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is also higher at GBP22,300. This increase in future
readmissions is due to the higher proportion of patients
being discharged to the community, where they are at
risk of readmission, and a lower proportion of patients
being admitted to long-term care, where they are not.
Due to the expected reduction in cases of KS from the
longer course of thiamine, the total expected cost of
long-term care is reduced to GBP12,700, yielding a total
expected cost over 35 years of GBP36,700 (95 % CI
GBP18,245 to GBP58,165).
Extending the admission by a further 5 days (10-day
admission) increases the cost of the index admission to
GBP3200. This is expected to reduce the risk of KS further,
leading to a greater proportion of the patient population
being discharged to the community (where they are at risk
of readmission). The combination of the greater length of
stay and increased proportion at risk of readmission means
that the expected cost of future ED attendances and
admissions is GBP43,300. However, the expected lower
risk of KS means the cost of long-term institutional and
community care totals GBP9300, yielding an expected cost
over 35 years of GBP55,700 (95 % CI GBP29,995 to
GBP84,224). This is higher than the expected cost from a
5-day admission: the extra cost of the longer admission
exceeds the cost savings from the reduced admissions to
long-term care (Table 2).
3.2 Sensitivity and Threshold Analyses
Threshold analysis comparing the cost difference between
2 and 5 days’ treatment suggests that the results are robust
to uncertainty in all model parameters, except for the
prevalence of WKS among patients presenting to the ED,
the probability of developing KS with no thiamine treat-
ment and the dose-response relationship to IV thiamine
(Fig. 2; Electronic Supplementary Material 6). The values
Table 2 Expected cost of admission and long-term care costs (present values, discounted at 3.5 %)
Days of
treatment
Cost (GBP) of
index admission
Cost (GBP) of
future admissions
Long-term community
care costs (GBP)
Long-term institutional
care costs (GBP)
Total cost (GBP) (95 % CI)
2 732 8688 17,604 96,677 123,701 (50,047 to 221,276)
5 1651 22,342 1958 10,778 36,729 (18,245 to 58,165)
10 3184 43,263 1421 7864 55,733 (29,995 to 84,224)
2–5a 83,722 (19,279 to 172,326)
5–10a -19,187 (-37,165 to -4486)
2–10a 64,535 (-1,007 to 151,594)
a Increment: e.g. cost of 2 days minus 5; positive indicates a saving, negative indicates increase in cost
Fig. 2 Tornado diagram comparing cost difference between 2- and 5-day admissions when individual parameters are varied between the ranges
described. A table of these results is in Electronic Supplementary File 6
The Long-Term Cost of Thiamine Treatments in Patients with WKS 211
at which a 5-day admission period becomes more expen-
sive than a 2-day admission are, however, at some distance
from the base-case assumptions (of note is that all three of
these parameters are based on expert opinion rather than
experimental evidence); for example, a 5-day admission
fails to become cost saving compared with a 2-day
admission only when the prevalence of WKS in the mod-
elled population presenting to the ED falls below 2.25 %.
The base-case value is 19 %. Similarly, the 5-day admis-
sion ceases to be cost saving when the probability of
developing KS without treatment is 10 % or less (base-case
value 84.4 %). Finally, only if IV thiamine is more than
eight times as effective at preventing KS than predicted by
the expert panel does the 5-day admission become more
expensive than a 2-day admission (i.e. when the dose-re-
sponse curve is shifted such that the probability of devel-
oping KS for a given dose of thiamine is only 0.12 times
that estimated by our expert panel, thus a 2-day course
prevents most cases of KS and the added benefit of the
extra 3 days is minimal).
3.3 Budget Impact
The figures presented above estimate the total cost per
patient presenting to the ED meeting the characteristics of
the population described in the methods. For the purpose of
calculating the potential budget impact of changing IV
thiamine replacement services, the following scenario,
defined by the authors to represent a ‘typical’ ED was
evaluated:
• Population a typical major ED unit seeing 500 unique
patients per annum, with 10 new patients joining the
prevalent population each year.
• Current policy to treat 75 % of patients with 2 days of
IV thiamine and 25 % of patients with 5 days of IV
thiamine.
• Proposed policy to treat 100 % of patients with 5 days
of IV thiamine.
Under the current policy, defined above, the present
value of expenditure on ED attendance and long-term care
for the prevalent cohort plus the incident cases over the
next 35 years is expected to be GBP64.1 million. Changing
the policy so that 100 % of patients receive 5 days of IV
thiamine treatment would be expected to reduce the value
of expenditure to GBP23.6 million, a GBP40.6 million
reduction (95 % CI GBP10.3 million to GBP82.4 million);
that is, an average reduction of GBP1.2 million per annum
(95 % CI GBP0.3 million to GBP2.3 million). The impact
on a specific ED would depend on the number of patients
presenting each year and the current treatment policies.
4 Discussion
Under the assumptions of this model, admitting or delaying
the discharge of patients considered at risk of WE increases
expected acute care costs, but is expected to result in a
substantial overall reduction in life-time costs to the public
sector (defined as NHS and social services and over a
35-year time horizon). This expected reduction is due to
the expected reduced risk of developing KS and, hence, the
requirement for admission to either a long-term institu-
tional facility or provision of a community-based care
package. The expected lifetime cost to the public sector for
admitting a patient for 2 days is GBP123,700. Extending
the admission to allow 5 days of IV thiamine replacement
increases the acute care cost; however, owing to the
expected reduction in risk of KS, the expected life-time
cost falls to GBP36,700: a total 70 % reduction in costs
incurred.
4.1 Implications for Practice
The assumption in this model is that patients can be
accommodated in the acute sector for an extended admis-
sion. Existing pressures on the acute sector may preclude
this in the short term. This analysis shows, however, that
prolonging admission by a few days has the possibility to
ease the long-term financial burden of these patients on the
public sector quite substantially. These results could,
therefore, be used as an input to a business case to explore
options for accommodating these patients or, at a mini-
mum, to investigate approaches by which the NHS can
trace patients for the subsequent few days post-discharge to
deliver the IV thiamine. The implications of this analysis
are that savings to the social care budget may be achieved
by increasing cost to the NHS budget. This suggests the
two organisations would need to co-operate in order to
realise the net public sector savings, a need recognised at a
more aggregate level too [41].
4.2 Strengths and Weaknesses
At the time of study completion, there were no reports of
any other analyses attempting to quantify the cost impact of
extending the admission of patients at risk of WKS to
ensure completion of a course of IV thiamine replacement
therapy.
The analysis is based on a relatively simple decision
model and presented in a manner that allows others to
replicate the work. Assumptions made in the model (for
example, the proportion of patients admitted to long-term
care) were conservative in that they would tend to
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underestimate any cost savings associated with reduced
rates of admission to long-term facilities.
It must be noted that this analysis focuses only on NHS
and social services costs. We do not explicitly measure and
value any health gains associated with the prevention of KS
or consider any broader social or emotional costs. The
impact of alcohol abuse is not only on the individual, but
extends to their family and society as a whole. Our estimate
is, therefore, an underestimate of the societal cost of
reducing the prevalence of KS. In 2003, the UK govern-
ment estimated the societal cost of alcohol misuse at
between GBP18 billion and GBP20 billion [42]. It is
plausible that a holistic strategy could reduce part of this
burden, one component of which should be ensuring that
patients who present to an ED receive sufficient thiamine
replacement where appropriate.
This analysis has a number of other limitations. First, the
entire area of IV thiamine replacement therapy in this
patient population is very under-researched. In particular,
no RCTs that demonstrate the efficacy or effectiveness of
IV thiamine replacement therapy are available, and the
optimum length of treatment is unknown. In the absence of
such experimental data, the relationship between length of
treatment and risk of developing KS was elicited from an
expert panel, using an established method [23], which
focuses on quantifying the uncertainty around experts’
beliefs (see Electronic Supplementary Material 3). Thus,
the model does not incorporate data on the dose-response
relationship, but rather the beliefs of experts as to the dose-
response relationship. In the absence of good-quality RCTs
or prospective cohort data, this approach is the next best
alternative. It should be noted that conducting such a
prospective RCT or cohort study would provide a much
firmer evidence base to incorporate into this model, but
would be extremely challenging due to the nature of the
patient group. However, our sensitivity analysis suggests
that a 2-day course of thiamine would have to be much
more effective at preventing KS as believed by our experts
to alter the conclusion of this study. This model relies
largely on the study completed by Victor and colleagues
[16], who succeeded in following up a cohort of 245
patients presenting with WE at their centres. Just over 100
of these patients were followed for up to 10 years; how-
ever, this study was conducted in the 1950s and 1960s.
Secondly, we chose a somewhat arbitrary 35-year time
horizon. This was intended to capture the majority of the
remaining lifespan of individuals in the model. Arguably a
longer time span would capture more costs of relevance,
but after discounting, the impact on present values will be
minimal. Furthermore, a shorter time horizon will under-
estimate future avoided costs, thus our analysis further
underestimates the true life-time net cost impact of the
longer acute admissions.
Finally, the model also may be considered conservative
since the same probability of repeat presentation to an ED
setting was applied to all scenarios of treatment duration in
the model. This was necessary because the potential cor-
relation between length of treatment and subsequent rate of
repeat presentation to the ED could not be robustly ascer-
tained from the available Hospital Episode Statistics and
prescription data and the range of possible International
Classification of Diseases (ICD) codes used to describe the
modelled population. It is, however, postulated that an
increased length of admission would reduce rates of re-
presentation, as patients receiving optimal dosing with IV
thiamine during their hospital stay might become better
informed about their condition and the potential conse-
quences of harmful drinking. It is also plausible that
improved cognitive functioning might allow them to
engage more effectively with healthcare professionals,
thereby improving their understanding of the condition and
their own decision making.
5 Conclusion
Admitting or delaying the discharge of patients presenting
to the ED until a minimum 5-day dose of IV thiamine can
be administered has the potential to save the public sector
substantial amounts of money over the longer term; for
example, extending the admission of a patient from 2 to
5 days for the purpose of IV thiamine replacement could
save the public sector GBP87,000 per patient over 35 years
(present value, discounted at 3.5 %). The model showed
that every extra GBP1 spent in acute care to manage WE is
estimated to save GBP6 in future social service costs.
Given perennial pressures on hospital beds, options
should be explored, whereby IV thiamine replacement
therapy can be delivered to these patients for the recom-
mended minimum 5-day dose either within an inpatient,
outpatient or community setting. While our analysis con-
siders only extending admissions within a general ward, the
cost implications of other approaches, such as specific
wards or units, should be carefully considered and this
analysis should form a useful part of the business case for
such an investment.
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